Abstract 1497P
Background
Resuscitation decisions in cancer patients continue to challenge Healthcare Professionals (HCPs) and often do not take place until clinical deterioration, risking futile Cardiopulmonary Resuscitation (CPR) attempts. This research investigated outcomes of In-Hospital Cardiopulmonary Arrest (IHCA) in advanced cancer within an NHS Trust in the UK, alongside viewpoints of HCPs.
Methods
This mixed-methods study comprised two components. Retrospective data analysis examined IHCA outcomes in patients with advanced cancer in Newcastle upon Tyne Hospitals NHS Foundation Trust (NUTH) between 2012-2022. Main outcomes included rate of Return of Spontaneous Circulation (ROSC) and survival to discharge. Other outcomes were median overall and post-discharge survival. A survey was distributed to senior HCPs in Acute Medicine (AM), Emergency Medicine (EM) and Oncology, to establish perceptions of CPR success in advanced cancer, and gather current opinion on issues surrounding resuscitation in this context.
Results
Among 83 patients, rate of ROSC was 33.7% and 9.6% survived to discharge. Among survivors, median overall survival was 2 days, and post-discharge survival 391 days. 92 HCPs responded to the survey. The mean likelihood of a patient with advanced cancer achieving ROSC was estimated at 13.4%. Oncologists were ranked the most appropriate HCP to discuss resuscitation, and outpatient clinic appointments the most suitable place. From analysis of text comments, important themes were (1) Place, person and timing, (2) Individualised decision-making, and (3) Improving patient understanding.
Conclusions
Survival following CPR is poor in advanced cancer, and fewer than 10% patients in this study gained any meaningful survival benefit. A collective approach is needed from HCPs to integrate personalised discussions about future care and resuscitation into routine cancer management. These should begin early rather than at a time of crisis, with someone the patient trusts. Blanket decisions are not suitable for any patient and cannot supersede clinical judgement alongside assessment of patient priorities and values.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Newcastle Hospitals Charity.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1594P - Cancer mortality in young population and estimated radon areas in Spain
Presenter: Miquel Ferriol-Galmés
Session: Poster session 10
1598P - Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study
Presenter: William Kelly
Session: Poster session 10
1600P - Phase II trial of pembrolizumab and lenvatinib in advanced neuroendocrine prostate cancer (NEPC)
Presenter: Ulka Vaishampayan
Session: Poster session 10
1601P - First results from ZZFIRST: A randomized phase II trial of enzalutamide (EZ) with or without talazoparib (TALA) in metastatic hormone-naïve prostate cancer (mHNPC)
Presenter: Joaquin Mateo
Session: Poster session 10
1602P - CBP-1018, Bi-ligand-drug conjugate (Bi-XDC) drug treated for metastatic castration resistant prostate cancer (mCRPC) patients from phase I study results
Presenter: Kaiwen Li
Session: Poster session 10
1603P - Updated safety and efficacy of tazemetostat (TAZ) plus enzalutamide (ENZ) in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Wassim Abida
Session: Poster session 10
1604P - PSMA-targeted radioligand therapy (RLT) with 131I-LNTH-1095 (1095) plus enzalutamide (enza) vs enza alone in chemotherapy-naïve patients (pts) whose piflufolastat F 18-avid metastatic castration-resistant prostate cancer (mCRPC) progressed on abiraterone (abi): ARROW
Presenter: Evan Yu
Session: Poster session 10
1605P - Opevesostat (MK-5684/ODM-208), an oral CYP11A1 inhibitor, in metastatic castration-resistant prostate cancer (mCRPC): Updated CYPIDES phase II results
Presenter: Karim Fizazi
Session: Poster session 10
1606P - Mature follow up of phase I dose finding trial of pembrolizumab (pembro) with AR inhibitors (ARI) and priming tumour-targeted radiation with anti-PSMA alpha emitter 225Ac-J591
Presenter: Aaron Holmes
Session: Poster session 10